CONTENTS

PERSPECTIVE


SHORT COMMUNICATIONS

Atorvastatin Treatment Induces Uptake and Efflux Transporters in Human Liver. Linda Björkhem-Bergman, Helena Bergström, Maria Johansson, Paolo Parini, Mats Eriksson, Anders Rape, and Lena Ekström ........... 1610

The Human UDP-Glucuronosyltransferase UGT2A1 and UGT2A2 Enzymes Are Highly Active in Bile Acid Glucuronidation. Martin Perreault, Louis Gauthier-Landry, Jocelyn Trottier, Mélanie Verreault, Patrick Caron, Moshe Finel, and Olivier Barbier ........... 1616

Characterization of Microsomal Glutathione S-Transferases MGST1, MGST2, and MGST3 in Cynomolgus Macaque. Yasuhiro Uno, Norie Murayama, Mutsuki Kunori, and Hiroshi Yamazaki ........... 1621

ARTICLES

Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects. Markus Walles, Thierry Wolf, Yi Jin, Michael Ritzau, Luc Alexis Leuthold, Joel Krauser, Hans-Peter Gschwind, David Carcache, Matthias Kittelmann, Magdalena Ociejea, Mike Ufer, Ralph Woessner, Abhijit Chakraborty, and Piet Swart ........... 1626

Downregulation of Sulfotransferase Expression and Activity in Diseased Human Livers. Emine B. Yalcin, Vijay More, Karissa L. Neira, Zhengiang James Lu, Nathan J. Cherrington, Angela L. Slitt, and Roberta S. King ........... 1642

The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine. Ariel R. Topletz, Jennifer B. Dennison, Robert J. Barbuch, Chad E. Hadden, Stephen D. Hall, and Jamie L. Renbarger ........... 1651

A Systematic Approach to Evaluate Herb-Drug Interaction Mechanisms: Investigation of Milk Thistle Extracts and Eight Isolated Constituents as CYP3A Inhibitors. Scott J. Brantley, Tyler N. Graf, Nicholas H. Oberlies, and Mary F. Paine ........... 1662

Formation of Threohydrobupropion from Bupropion Is Dependent on 11β-Hydroxysteroid Dehydrogenase 1. Arne Meyer, Anna Vuorinen, Agnieszka E. Zielinska, Pettra Stajhjar, Gareth G. Lavery, Daniela Schuster, and Alex Odermatt ........... 1671


The Role of Human Cytochrome P450 Enzymes in the Formation of 2-Hydroxymetronidazole: CYP2A6 is the High Affinity (Low Km) Catalyst. Robin E. Pearce, Michael Cohen-Wolkowiez, Mario R. Sampson, and Gregory L. Kearns ........... 1686

Intestinal First-Pass Metabolism by Cytochrome P450 and Not P-Glycoprotein Is the Major Barrier to Amprenavir Absorption. Matthew B. Dufek, Arlene S. Bridges, and Dhiren R. Thakker ........... 1695

Continued on next page
Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism. Thomas M. Bridges, Jerri M. Rook, Meredith J. Noetzel, Ryan D. Morrison, Ya Zhou, Rocco D. Gogliotti, Paige N. Vinson, Zixiu Xiang, Carrie K. Jones, Colleen M. Niswender, Craig W. Lindsley, Shaun R. Stauffer, P. Jeffrey Conn, and J. Scott Daniels

Inhibition of Cytochrome P450 Enzymes by the E- and Z-Isomers of Norendoxifen. Jinzhong Liu, Peter J. Flockhart, Deshun Lu, Wei Lv, Wenjie Jessie Lu, Xu Han, Mark Cushman, and David A. Flockhart

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Proposed binding modes of R-bupropion and S-bupropion in the ligand-binding pocket of human 11b-HSD1. See article by Meyer et al. on page 1671 of this issue.